2019 China'S Big Health Industry Summit: Focusing On Healthy Corporate Social Responsibility And Exploring New Opportunities For Medical Treatment Under The New Deal

In November 19th, the China business report leader, the twenty-first Century economic report, successfully held the 2019 China Great Health Industry Summit in Guangzhou. This summit will focus on the social responsibility of big health industry, the response of pharmaceutical enterprises under "policy city", and the discussion of new opportunities for medical investment and medical biology. The summit invited government agencies, industry leaders, technology pioneers and investment institutions to gather together to promote the development of the health industry.

Zhang Zhibing, general manager of Southern financial and media group, pointed out that health care is one of the industries most affected by policies. In 2019, it was precisely the year when policy was most concentrated, released, landed and fermented. All kinds of heavy policies have been put forward, reshaping the industrial structure from all angles, reflecting the firm determination of the government to reduce prices, control fees and improve quality.

As an important link, the summit released the report on social responsibility of 2019 health care listed companies as a social responsibility report released by the economic report second degrees in twenty-first Century. The report is based on the multiple evaluation bodies such as the "Sustainability Report Guide" organized by the global reporting initiative, and has pioneered the quantitative evaluation system of the social responsibility of medical and health enterprises. It has continued to improve and refine the seven evaluation dimensions of economic performance and market performance, employee rights and environmental protection, etc., and has scored the scores of nearly 300 medical listed companies, and has made an in-depth analysis of the top five enterprises.

Under the cooling of medical and health investment, investors and enterprises reexamine the industry and become more rational and rational.

Medical reform is bold and resolute.

This year, the policy of heavy health is intensive and weightier.

The new round of volume procurement, the adjustment and negotiation of medical insurance catalogues, the reduction of rare diseases, the encouragement of generic drugs, the unified medical insurance information system construction, the adoption of the "drug management law" overhaul, and the implementation of the "healthy China action - cancer prevention and treatment plan (2019 to 2022)", all of which reshaped the industry pattern from a different angle, and put forward a higher and renewed test of corporate social responsibility.

In September this year, the results of the procurement of the second wheel volume announced that the price of many drugs was known as "floor price" and "cabbage price" for the winning bid price.

With the volume of procurement, the multinational pharmaceutical companies "overdue" the original research drugs, facing the real "patent cliff", but the generic drug based local pharmaceutical companies are also very difficult, during which the successful pharmaceutical companies are facing a sharp decline in profits, the need to expand more powerful product lines and high profit drugs to protect the supply; and the unsuccessful pharmaceutical companies, the market space is compressed, these pharmaceutical companies are looking for a breakthrough in the transformation of the dilemma.

In this historical stage of transition, the social responsibility of pharmaceutical companies has not been reduced. Instead, higher standards should be applied to push forward the new rules of the industry. In the new situation, how to comply with business ethics, ensure production safety, product quality, protect the legitimate rights and interests of employees, occupational health, and compress costs under the compression of profit space, and do not pollute the environment, are the challenges facing enterprises.

In August 20th this year, the State Health Protection Bureau and the Ministry of human resources and social security issued the notice on Issuing the catalogue of national basic medical insurance, work-related injury insurance and maternity insurance medicines (Medicare [2019] 46), which announced the list of drugs for the basic access to the national basic medical insurance, industrial injury insurance and maternity insurance, that is, the national health insurance directory. In November 11th, the national health insurance agency officially started the round of drug price negotiations.

Under these new policies, how to improve the drug accessibility of patients, reasonably cut down the cost of health care, and benefit more patients, is also an important indication of corporate social responsibility.

According to IQVIA data, the growth rate of blood and hematopoietic organs, anti-tumor and immunomodulators in China's hospital drug market was the highest in 2018, 13.1% and 12% respectively. In terms of market performance, drug penetration into the national health insurance is obvious.

In the second quarter of 2019, the overall market was significantly boosted by the continuing impact of the medical insurance negotiations and the acceleration of the implementation of drug centralized bidding. Some drugs are facing the fate of being kicked out of health care. Another part of the drugs are ready to enter the list. About 70 drugs need to take part in the negotiations.

While medical insurance funds are constantly making room for innovative drugs, anticancer drugs and rare disease drugs, how to balance the relationship between budgets and values, how to ensure fairness and accessibility, has become a test topic for all parties.

Zhang Zhibing said that under the new situation, the people's demand for medical health has been increasing. The public has put forward higher requirements for the quality of medical and health products and the reputation of enterprises. The enterprises in it are also thinking about ensuring the quality of products while fulfilling their social responsibilities. These elements will gradually become an important part of the enterprise brand and become a significant sign of core competitiveness.

Reconstruction of social responsibility

In recent years, China's big health industry has rapidly grown into a national strategic industry. However, with the ferment of fake (expired) vaccine and API, social responsibility and product quality and safety have become the key words in the medical and health industry. The lack of corporate social responsibility and the crisis of ethics and morality have led to the sustainable development of the whole industry.

The continuous promotion of "healthy China" strategy brings opportunities for the development of the big health market, and the implementation of social responsibility is the basis for the development of the industry. Based on media responsibility, the twenty-first Century economic report has repeatedly stressed that fulfilling social responsibility is the bottom line for health industry to stick to.

Against this background, the twenty-first Century economic report has been engaged in the medical and health report collection and editing team for a long time. It has selected about 300 A shares and Hong Kong stock medical and health listed companies again. It has quantified the fulfillment of social responsibility of every company in terms of economic efficiency, environmental protection, product quality and safety, fair competition, employee remuneration, social welfare and social responsibility report.

From the data point of view, in the issuance of social responsibility reports, biopharmaceutical sector enterprises accounted for 117 out of 10 enterprises, accounting for 60% of the statistical data; 36 of the medical device consumables sector accounted for less than 10, accounting for 65% of the statistics; 21 of the 10 10 medical service sectors accounted for 55% of the total statistics.

In terms of social responsibility, Chinese medicine has been awarded a full score of 20 points. 59 biopharmaceutical sector enterprises accounted for zero points in the social responsibility report, accounting for 37% of the statistics. 23 of the medical device consumables sector got zero points, accounting for 42% of the statistics. In terms of social welfare, there were 11 enterprises with zero scores, accounting for 29% of the statistics.

In terms of environmental protection, biopharmaceutical sector enterprises have a total of 63 enterprises below 10 points, accounting for 40% of the statistics; 34 of the medical device consumables enterprises are below 10, accounting for 62% of the statistics; 25 of the medical service enterprises are below 10, accounting for 66% of the statistics.

In terms of accepting administrative penalties or serious violations, 195 Biopharmaceutical Enterprises received more than 110 administrative penalties or serious violations, accounting for 56% of the total statistics; 28 of the medical device consumables enterprises received administrative penalties or serious violations, accounting for 51% of the statistics; 20 of the medical service enterprises received administrative penalties or serious violations, accounting for 53% of the statistics.

From the above data, China's bio pharmaceuticals, medical equipment consumables, medical services and other enterprises in the social responsibility, social welfare, environmental protection and other aspects are still facing further room for improvement.

At present, the social responsibility of pharmaceutical enterprises has gradually become an important part of the brand and core competitiveness of enterprises. As the soft power of enterprises in the new historical opportunities, it becomes more and more important. And in the international community, more attention has been paid to corporate social responsibility. At present, Chinese pharmaceutical enterprises are gradually stepping towards internationalization with the improvement of their strength.